-
1
-
-
67449150231
-
Increasing burden of melanoma in the United States
-
E. Linos, S.M. Swetter, M.G. Cockburn, G. A. Colditz, andC.A. Clarke, "Increasing burden of melanoma in the United States, " Journal of Investigative Dermatology, vol. 129, no. 7, pp. 1666-1674, 2009.
-
(2009)
Journal of Investigative Dermatology
, vol.129
, Issue.7
, pp. 1666-1674
-
-
Linos, E.1
Swetter, S.M.2
Cockburn, M.G.3
Colditz, C.A.4
Clarke, G.A.5
-
2
-
-
84872967522
-
Cancer statistics, 2013
-
R. Siegel, D. Naishadham, and A. Jemal, "Cancer statistics, 2013, " CA:ACancer Journal for Clinicians, vol. 63, no. 1, pp. 11-30, 2013.
-
(2013)
CA:ACancer Journal for Clinicians
, vol.63
, Issue.1
, pp. 11-30
-
-
Siegel, R.1
Naishadham, D.2
Jemal, A.3
-
3
-
-
74949143594
-
Final version of 2009 AJCC melanoma staging and classification
-
C. M. Balch, J. E. Gershenwald, S.-J. Soong et al., "Final version of 2009 AJCC melanoma staging and classification, " Journal of Clinical Oncology, vol. 27, no. 36, pp. 6199-6206, 2009.
-
(2009)
Journal of Clinical Oncology
, vol.27
, Issue.36
, pp. 6199-6206
-
-
Balch, C.M.1
Gershenwald, J.E.2
Soong, S.-J.3
-
4
-
-
79959795786
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
-
P. B. Chapman, A. Hauschild, C. Robert et al., "Improved survival with vemurafenib in melanoma with BRAF V600E mutation, " New England Journal of Medicine, vol. 364, no. 26, pp. 2507-2516, 2011.
-
(2011)
New England Journal of Medicine
, vol.364
, Issue.26
, pp. 2507-2516
-
-
Chapman, P.B.1
Hauschild, A.2
Robert, C.3
-
5
-
-
33947101019
-
Patterns of somatic mutation in human cancer genomes
-
C. Greenman, P. Stephens, R. Smith et al., "Patterns of somatic mutation in human cancer genomes, " Nature, vol. 446, pp. 153-158, 2007.
-
(2007)
Nature
, vol.446
, pp. 153-158
-
-
Greenman, C.1
Stephens, P.2
Smith, R.3
-
6
-
-
84864285704
-
Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, openlabel, phase 3 randomised controlled trial
-
A. Hauschild, J.-J. Grob, L. V. Demidov et al., "Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, openlabel, phase 3 randomised controlled trial, " The Lancet, vol. 380, no. 9839, pp. 358-365, 2012.
-
(2012)
The Lancet
, vol.380
, Issue.9839
, pp. 358-365
-
-
Hauschild, A.1
Grob, J.-J.2
Demidov, L.V.3
-
8
-
-
67650491811
-
Treatment of metastatic melanoma: An overview
-
S. Bhatia, S. S. Tykodi, and J. A. Thompson, "Treatment of metastatic melanoma: an overview, " Oncology, vol. 23, no. 6, pp. 488-496, 2009.
-
(2009)
Oncology
, vol.23
, Issue.6
, pp. 488-496
-
-
Bhatia, S.1
Tykodi, S.S.2
Thompson, J.A.3
-
9
-
-
84873819555
-
Which drug, and when, for patients with BRAF-mutant melanoma?
-
S. Jang and M. B. Atkins, "Which drug, and when, for patients with BRAF-mutant melanoma?" The Lancet Oncology, vol. 14, no. 2, pp. e60-e69, 2013.
-
(2013)
The Lancet Oncology
, vol.14
, Issue.2
, pp. e60-e69
-
-
Jang, S.1
Atkins, M.B.2
-
10
-
-
84888861162
-
Emerging BRAF inhibitors for melanoma
-
F. Sabbatino, Y. Wang, X. Wang, S. Ferrone, and C. R. Ferrone, "Emerging BRAF inhibitors for melanoma, " Expert Opinion on Emerging Drugs, vol. 18, no. 4, pp. 431-443, 2013.
-
(2013)
Expert Opinion on Emerging Drugs
, vol.18
, Issue.4
, pp. 431-443
-
-
Sabbatino, F.1
Wang, Y.2
Wang, X.3
Ferrone, S.4
Ferrone, C.R.5
-
11
-
-
84879467934
-
Ipilimumab, vemurafenib, dabrafenib, and trametinib: Synergistic competitors in the clinical management of BRAF mutant malignantmelanoma
-
J. J. Luke and F. S. Hodia, "Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignantmelanoma, " The Oncologist, vol. 18, no. 6, pp. 717-725, 2013.
-
(2013)
The Oncologist
, vol.18
, Issue.6
, pp. 717-725
-
-
Luke, J.J.1
Hodia, F.S.2
-
12
-
-
84925662170
-
-
National Comprehensive Cancer Network (NCCN) , National Comprehensive Cancer Network (NCCN), Philadelphia, Pa, USA
-
National Comprehensive Cancer Network (NCCN), National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Antiemesis (Version 2.2014), National Comprehensive Cancer Network (NCCN), Philadelphia, Pa, USA, 2014, http://www.nccn.org/professionals/physician gls/pdf/ antiemesis.pdf.
-
(2014)
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Antiemesis (Version 2 2014)
-
-
-
15
-
-
84952995084
-
-
Los Angeles, Calif, USA
-
J. B. Davis, Medical Fees, Practice Management Information Corporation, Los Angeles, Calif, USA, 2013.
-
(2013)
Medical Fees, Practice Management Information Corporation
-
-
Davis, J.B.1
-
16
-
-
84875929603
-
Treatment of BRAF inhibitor-induced hyperkeratosis
-
J. E. Battley, E. Lenihan, H. P. Redmond, M. Murphy, and D. G. Power, "Treatment of BRAF inhibitor-induced hyperkeratosis, " Acta Oncologica, vol. 52, no. 4, pp. 874-877, 2013.
-
(2013)
Acta Oncologica
, vol.52
, Issue.4
, pp. 874-877
-
-
Battley, J.E.1
Lenihan, E.2
Redmond, H.P.3
Murphy, M.4
Power, D.G.5
-
17
-
-
84859443897
-
Fee comparisons of treatments for nonmelanoma skin cancer in a private practice academic setting
-
L. S. Wilson, M. Pregenzer, R. Basu et al., "Fee comparisons of treatments for nonmelanoma skin cancer in a private practice academic setting, " Dermatologic Surgery, vol. 38, no. 4, pp. 570-584, 2012.
-
(2012)
Dermatologic Surgery
, vol.38
, Issue.4
, pp. 570-584
-
-
Wilson, L.S.1
Pregenzer, M.2
Basu, R.3
-
18
-
-
0030708771
-
Guidelines on acute infectious diarrhea in adults. The Practice Parameters Committee of the American College of Gastroenterology
-
H. L. DuPont, "Guidelines on acute infectious diarrhea in adults. The Practice Parameters Committee of the American College of Gastroenterology, " The American Journal of Gastroenterology, vol. 92, no. 11, pp. 1962-1975, 1997.
-
(1997)
The American Journal of Gastroenterology
, vol.92
, Issue.11
, pp. 1962-1975
-
-
Dupont, H.L.1
-
19
-
-
82355163146
-
Clinical presentation andmanagement of hand-foot skin reaction associated with sorafenib in combinationwith cytotoxic chemotherapy: Experience in breast cancer
-
P. Gomez and M. E. Lacouture, "Clinical presentation andmanagement of hand-foot skin reaction associated with sorafenib in combinationwith cytotoxic chemotherapy: experience in breast cancer, " The Oncologist, vol. 16, no. 11, pp. 1508-1519, 2011.
-
(2011)
The Oncologist
, vol.16
, Issue.11
, pp. 1508-1519
-
-
Gomez, P.1
Lacouture, M.E.2
-
20
-
-
34447095906
-
Palmar-plantar erythrodysesthesia (PPE): A literature review with commentary on experience in a cancer centre
-
J. D. Webster-Gandy, C. How, and K. Harrold, "Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre, " European Journal of Oncology Nursing, vol. 11, no. 3, pp. 238-246, 2007.
-
(2007)
European Journal of Oncology Nursing
, vol.11
, Issue.3
, pp. 238-246
-
-
Webster-Gandy, J.D.1
How, C.2
Harrold, K.3
-
21
-
-
84896714827
-
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study
-
G. A. McArthur, P. B. Chapman, C. Robert et al., "Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study, " The Lancet Oncology, vol. 15, no. 3, pp. 323-332, 2014.
-
(2014)
The Lancet Oncology
, vol.15
, Issue.3
, pp. 323-332
-
-
McArthur, G.A.1
Chapman, P.B.2
Robert, C.3
-
23
-
-
0020445539
-
Aconvenient approximation of life expectancy (the 'DEALE'). I. Validation of the method
-
J.R. Beck, J. P. Kassirer, and S. G. Pauker, "Aconvenient approximation of life expectancy (the 'DEALE'). I. validation of the method, " The American Journal of Medicine, vol. 73, no. 6, pp. 883-888, 1982.
-
(1982)
The American Journal of Medicine
, vol.73
, Issue.6
, pp. 883-888
-
-
Beck, J.R.1
Kassirer, J.P.2
Pauker, S.G.3
-
24
-
-
0026937441
-
New DEALEs: Other approximations of life expectancy
-
E. Keeler and R. Bell, "New DEALEs: other approximations of life expectancy, " MedicalDecisionMaking, vol. 12, no. 4, pp. 307-311, 1992.
-
(1992)
MedicalDecisionMaking
, vol.12
, Issue.4
, pp. 307-311
-
-
Keeler, E.1
Bell, R.2
-
25
-
-
68149158282
-
Societal preference values for advanced melanoma health states in the United Kingdom and Australia
-
K. M. Beusterien, S. M. Szabo, S. Kotapati et al., "Societal preference values for advanced melanoma health states in the United Kingdom and Australia, " British Journal of Cancer, vol. 101, no. 3, pp. 387-389, 2009.
-
(2009)
British Journal of Cancer
, vol.101
, Issue.3
, pp. 387-389
-
-
Beusterien, K.M.1
Szabo, S.M.2
Kotapati, S.3
-
26
-
-
1842607638
-
A catalog of dermatology utilities: A measure of the burden of skin diseases
-
S. C. Chen, A. M. Bayoumi, S. L. Soon et al., "A catalog of dermatology utilities: a measure of the burden of skin diseases, " Journal of Investigative Dermatology Symposium Proceedings, vol. 9, no. 2, pp. 160-168, 2004.
-
(2004)
Journal of Investigative Dermatology Symposium Proceedings
, vol.9
, Issue.2
, pp. 160-168
-
-
Chen, S.C.1
Bayoumi, A.M.2
Soon, S.L.3
-
27
-
-
33748558111
-
Health state utilities for metastatic breast cancer
-
A. Lloyd, B. Nafees, J. Narewska, S. Dewilde, and J. Watkins, "Health state utilities for metastatic breast cancer, " British Journal of Cancer, vol. 95, no. 6, pp. 683-690, 2006.
-
(2006)
British Journal of Cancer
, vol.95
, Issue.6
, pp. 683-690
-
-
Lloyd, A.1
Nafees, B.2
Narewska, J.3
Dewilde, S.4
Watkins, J.5
-
28
-
-
84903741191
-
Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: Quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine
-
J. J. Grob, M. M. Amonkar, S. Martin-Algarra et al., "Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine, " Annals of Oncology, vol. 25, no. 7, pp. 1428-1436, 2014.
-
(2014)
Annals of Oncology
, vol.25
, Issue.7
, pp. 1428-1436
-
-
Grob, J.J.1
Amonkar, M.M.2
Martin-Algarra, S.3
-
29
-
-
40149086980
-
Cost of neutropenic complications of chemotherapy
-
D. Weycker, J. Malin, J. Edelsberg, A. Glass, M. Gokhale, and G. Oster, "Cost of neutropenic complications of chemotherapy, " Annals of Oncology, vol. 19, no. 3, pp. 454-460, 2008.
-
(2008)
Annals of Oncology
, vol.19
, Issue.3
, pp. 454-460
-
-
Weycker, D.1
Malin, J.2
Edelsberg, J.3
Glass, A.4
Gokhale, M.5
Oster, G.6
-
30
-
-
0037443674
-
Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors
-
L. S. Elting, S. B. Cantor, C. G. Martin et al., "Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors, " Cancer, vol. 97, no. 6, pp. 1541-1550, 2003.
-
(2003)
Cancer
, vol.97
, Issue.6
, pp. 1541-1550
-
-
Elting, L.S.1
Cantor, S.B.2
Martin, C.G.3
-
31
-
-
52649097540
-
Optimal cost-effectiveness decisions: The role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI)
-
G. R. Barton, A. H. Briggs, and E. A. L. Fenwick, "Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI), " Value in Health, vol. 11, no. 5, pp. 886-897, 2008.
-
(2008)
Value in Health
, vol.11
, Issue.5
, pp. 886-897
-
-
Barton, G.R.1
Briggs, A.H.2
Fenwick, E.A.L.3
-
32
-
-
84910598214
-
Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma
-
P. Curl, I. Vujic, L. J. van 't Veer, S. Ortiz-Urda, J. G. Kahn, and A. T. Slominski, "Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma, " PLoS ONE, vol. 9, no. 9, 2014.
-
(2014)
PLoS ONE
, vol.9
, Issue.9
-
-
Curl, P.1
Vujic, I.2
Van Veer, L.J.3
Ortiz-Urda, S.4
Kahn, J.G.5
Slominski, A.T.6
-
33
-
-
1542634778
-
Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: A critical appraisal
-
C. Evans, M. Tavakoli, and B. Crawford, "Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal, " Health Care Management Science, vol. 7, no. 1, pp. 43-49, 2004.
-
(2004)
Health Care Management Science
, vol.7
, Issue.1
, pp. 43-49
-
-
Evans, C.1
Tavakoli, M.2
Crawford, B.3
-
34
-
-
84907360483
-
Updating cost-effectiveness-The curious resilience of the 50, 000-per-QALY threshold
-
P. J. Neumann, J. T. Cohen, and M. C. Weinstein, "Updating cost-effectiveness-the curious resilience of the 50, 000-per-QALY threshold, "TheNewEngland Journal ofMedicine, vol. 371, no. 9, pp. 796-797, 2014.
-
(2014)
The New England Journal OfMedicine
, vol.371
, Issue.9
, pp. 796-797
-
-
Neumann, P.J.1
Cohen, J.T.2
Weinstein, M.C.3
-
35
-
-
84879021680
-
Ipilimumab in 2nd line treatment of patients with advanced melanoma: A cost-effectiveness analysis
-
V. Barzey, M. B. Atkins, L. P. Garrison, Y. Asukai, S. Kotapati, and J. R. Penrod, "Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis, " Journal of Medical Economics, vol. 16, no. 2, pp. 202-212, 2013.
-
(2013)
Journal of Medical Economics
, vol.16
, Issue.2
, pp. 202-212
-
-
Barzey, V.1
Atkins, M.B.2
Garrison, L.P.3
Asukai, Y.4
Kotapati, S.5
Penrod, J.R.6
-
36
-
-
84877327961
-
NICE's end of life decision making scheme: Impact on population health
-
Article ID f1363
-
M. Collins and N. Latimer, "NICE's end of life decision making scheme: impact on population health, " British Medical Journal, vol. 346, no. 7905, Article ID f1363, 2013.
-
(2013)
British Medical Journal
, vol.346
, Issue.7905
-
-
Collins, M.1
Latimer, N.2
-
37
-
-
85020643915
-
-
American Cancer Society
-
American Cancer Society, Cancer Drug Coverage in Health InsuranceMarketplace Plans, 2014, http://www.acscan.org/content/ wp-content/uploads/2014/03/Marketplace formularies whitepaper.pdf.
-
(2014)
Cancer Drug Coverage in Health InsuranceMarketplace Plans
-
-
-
39
-
-
0031017851
-
Patient preferences for oral versus intravenous palliative chemotherapy
-
G. Liu, E. Franssen, M. I. Fitch, and E. Warner, "Patient preferences for oral versus intravenous palliative chemotherapy, " Journal of Clinical Oncology, vol. 15, no. 1, pp. 110-115, 1997.
-
(1997)
Journal of Clinical Oncology
, vol.15
, Issue.1
, pp. 110-115
-
-
Liu, G.1
Franssen, E.2
Fitch, M.I.3
Warner, E.4
-
40
-
-
41849112354
-
NCCN task force report: Oral chemotherapy
-
S. N. Weingart, P. B. Bach, K. Eng et al., "NCCN task force report: oral chemotherapy, " Journal of the National Comprehensive Cancer Network, vol. 6, supplement 3, pp. S1-S14, 2008.
-
(2008)
Journal of the National Comprehensive Cancer Network
, vol.6
, pp. S1-S14
-
-
Weingart, S.N.1
Bach, P.B.2
Eng, K.3
|